<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-72 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-72</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-72</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-4.html">extraction-schema-4</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <p><strong>Paper ID:</strong> paper-4eedd767df97fc2ae581156a0ab11d428c3fc622</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/4eedd767df97fc2ae581156a0ab11d428c3fc622" target="_blank">Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.</a></p>
                <p><strong>Paper Venue:</strong> Journal of the American Medical Association (JAMA)</p>
                <p><strong>Paper TL;DR:</strong> In this review of candidate gene association studies, nearly one-third of gene-variant cancer associations were statistically significant, with variants in genes encoding for metabolizing enzymes among the most consistent and highly significant associations.</p>
                <p><strong>Cost:</strong> 0.026</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e72.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e72.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>GSTM1 null</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Glutathione S-transferase M1 deletion (GSTM1 null)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Homozygous deletion of GSTM1 abolishes enzyme activity of a phase II glutathione S-transferase that detoxifies electrophiles and products of oxidative stress, increasing susceptibility to tobacco carcinogens.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (review of meta- and pooled analyses)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Meta-analyses of lung cancer case-control and nested case-control studies; lung-specific summary reported from 19 studies with 3,532 cases (as reported in Table 2 of this paper). Populations are multiethnic across included studies; ages not uniformly reported in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>GSTM1 null (homozygous gene deletion)</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>Loss of GSTM1 enzymatic activity reduces phase II detoxification of polycyclic aromatic hydrocarbons (PAHs) and oxidative products from tobacco smoke, impairing detoxification and excretion of carcinogens.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>OR = 1.20 (95% CI 1.14–1.26), p ≈ 6×10^-10 (lung cancer, 19 studies, N cases = 3,532) (Table 2)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Generally 'tobacco smoking' or smoking status; some included studies stratified by smoking or reported cumulative cigarette smoking in follow-ups, but no standardized pack‑year metric is reported across the meta-analyses in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td>Phase II detoxification deficiency (impaired conjugation of electrophiles/PAH metabolites)</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke (PAHs and oxidative stress products) explicitly cited as substrates detoxified by GSTM1</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>GSTM1 encodes a conjugating enzyme that removes reactive electrophiles and PAH metabolites. Deletion (GSTM1 null) leads to complete loss of enzyme activity, reducing detoxification of tobacco carcinogens and increasing the burden of DNA‑damaging intermediates, thereby raising cancer risk among exposed individuals.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Paper notes gene-environment interactions are plausible (e.g., genotype modifies effect of tobacco exposure) though power in meta-analyses to assess interactions is limited; GSTM1 null is mechanistically relevant to tobacco smoke exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Deletion of GSTM1 (GSTM1 null) is a reproducible genetic factor associated with increased lung cancer risk; loss of phase II detoxification capacity is a plausible mechanistic explanation for why some smokers develop lung cancer while others do not.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e72.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>GSTT1 null</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Glutathione S-transferase T1 deletion (GSTT1 null)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Homozygous deletion of GSTT1 causes loss of a phase II enzyme involved in detoxification of reactive electrophiles and PAH metabolites, altering susceptibility to tobacco-related carcinogenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (review of meta- and pooled analyses)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Meta-analyses of lung cancer case-control studies summarized in this review; lung-specific GSTT1 summary: 17 studies, 3,484 cases (Table 2). Populations multiethnic.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>GSTT1 null (homozygous gene deletion)</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>Loss of GSTT1 enzyme activity reduces conjugation and elimination of electrophilic metabolites (including products of tobacco smoke), impairing detoxification.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>OR = 1.19 (95% CI 1.14–1.29), p ≈ 3.5×10^-10 (lung cancer, 17 studies, N cases = 3,484) (Table 2)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>General tobacco smoking / smoking status mentioned; specific pack-year measures not provided in the aggregated summaries.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td>Phase II detoxification deficiency (reduced conjugation and clearance of PAH and oxidative metabolites)</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke (PAHs, oxidative products) identified as relevant substrates</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>GSTT1 is involved in elimination of carcinogens (oxidative stress products, PAHs). Homozygous deletion eliminates enzymatic activity, diminishing detoxification of tobacco-derived carcinogens and increasing DNA damage burden and cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Paper emphasizes that genotype-by-smoking interactions are biologically plausible but most meta-analyses lack power to robustly test interactions; GSTT1 alters response to tobacco carcinogens.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>GSTT1 null is associated with modestly increased lung cancer risk; impaired phase II metabolism provides a mechanistic rationale for interindividual differences in smoking-related lung cancer susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e72.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NAT2 slow acetylator</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>N-acetyltransferase 2 slow-acetylator phenotype</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Polymorphic NAT2 alleles produce a slow-acetylator phenotype that changes activation/detoxification of aromatic and heterocyclic amines, modulating cancer risk from tobacco carcinogens.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis (NAT2 meta-analyses reviewed; strongest evidence for bladder cancer, discussed mechanistically for tobacco exposures)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Aggregated studies across cancer sites; NAT2 slow-acetylator prevalence cited (European whites ~56%, Asians ~11%); lung-specific data not emphasized in this review (primary NAT2 association reported for bladder cancer).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>NAT2 slow-acetylator alleles (multiple non-synonymous polymorphisms)</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>NAT2 enzyme catalyzes N-acetylation of aromatic/heterocyclic amines; slow-acetylator alleles result in decreased catalytic activity and altered detoxification/activation balance of tobacco-derived amines.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>For bladder cancer (example in review): OR = 1.46 (95% CI 1.26–1.68), p = 2.5×10^-7; lung-specific ORs not provided in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Tobacco smoke exposure discussed qualitatively (aromatic amines from tobacco as substrates); no uniform smoking metric reported in NAT2 summaries here.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td>Phase II acetylation capacity (altered activation/detoxification of aromatic amines from tobacco)</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke aromatic/heterocyclic amines (critical substrate for NAT2-mediated metabolism)</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>Slow acetylation reduces detoxification of aromatic amines (increasing bladder cancer risk) but can reduce activation of other carcinogens (decreasing risk at other sites). For tobacco-related cancers, NAT2 phenotype changes internal dose of active carcinogenic metabolites and thus susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified for lung in this review (strongest effect described for bladder cancer)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Well-established gene-environment interaction described for NAT2 × smoking in bladder cancer (review discusses NAT2 as modifying smoking-related carcinogenesis); general point made that effects differ by tissue because of activation vs detoxification roles.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Polymorphisms that alter metabolic activation/detoxification (NAT2 slow acetylator) change internal exposure to tobacco-derived amines and thereby help explain why smokers differ in cancer susceptibility; effect is tissue-specific (e.g., bladder).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e72.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CYP1A1 variants</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cytochrome P450 1A1 polymorphisms (various alleles, e.g., exon7/Leu432Val, Msp1 T3801C)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>CYP1A1 is a phase I enzyme involved in activation of PAHs and other procarcinogens in tobacco smoke; polymorphisms can increase activation and cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (lung and other cancer meta-analyses reviewed)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Lung-specific meta-analyses summarized in Table 2: e.g., CYP1A1 exon7 (AG+GG vs AA) lung OR = 1.61 (p=0.0001) from 11 studies, N cases = 1,176; other CYP1A1 comparisons and esophageal cancer associations also reported.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>CYP1A1 polymorphisms (exon7 variant/Leu432Val; Msp1 T3801C)</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>CYP1A1 encodes a phase I enzyme that bioactivates PAHs and tobacco procarcinogens to reactive intermediates; variant alleles can alter enzyme activity and increase formation of DNA-reactive metabolites.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>Lung: CYP1A1 exon7 (AG+GG vs AA) OR = 1.61 (95% CI 1.24–2.08), p = 0.0001 (11 studies, N cases = 1,176) (Table 2). Other CYP1A1 comparisons (e.g., Msp1) show increased ORs in some cancers (e.g., esophageal).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Tobacco smoke / smoking status as source of PAHs; meta-analyses aggregated studies with varying smoking measurement; no single standardized pack-year measure across reports.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td>Phase I activation (increased bioactivation of tobacco procarcinogens)</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke (PAHs)—primary environmental substrate whose bioactivation is catalyzed by CYP1A1</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>CYP1A1 variants can increase metabolic activation of PAHs in tobacco smoke to reactive intermediates that form DNA adducts; individuals with higher-activity variants generate more DNA damage for a given tobacco exposure, increasing cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall; CYP1A1 also implicated in esophageal cancer in this review)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Implied gene-environment interaction: variant increases harm from tobacco exposure; however, meta-analyses often lacked power to robustly quantify interactions.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Variants in phase I enzymes (CYP1A1) that enhance activation of tobacco procarcinogens are associated with higher lung cancer risk, explaining part of interindividual susceptibility among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e72.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>XPD Lys751Gln</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>XPD (ERCC2) Lys751Gln nucleotide excision repair polymorphism</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A common polymorphism in the XPD (ERCC2) gene, involved in nucleotide excision repair, that has been associated with modestly increased lung cancer risk, likely via reduced DNA repair capacity of bulky adducts from tobacco smoke.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (reviewed meta-analyses of DNA repair gene polymorphisms and lung cancer)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Lung-specific meta-analysis results summarized: XPD Lys751Gln (AC+CC vs AA) OR = 1.30 (95% CI 1.13–1.49), p = 0.0002; 15 studies, N cases = 5,004 (Table 2).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>XPD Lys751Gln (also reported as ERCC2 Lys751Gln)</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>XPD/ERCC2 participates in nucleotide excision repair of bulky DNA adducts; the 751Gln variant is thought to alter protein function and reduce repair efficiency of tobacco-induced DNA lesions.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>OR = 1.30 (95% CI 1.13–1.49), p = 0.0002 (lung cancer; 15 studies, N cases = 5,004) (Table 2)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Tobacco exposure broadly referenced as source of bulky DNA adducts; specific exposure metrics not standardized across included studies.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td>Deficient/altered nucleotide excision repair capacity (reduced repair of bulky adducts from tobacco carcinogens)</td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke (formation of bulky DNA adducts repaired by NER pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>XPD is essential for nucleotide excision repair of bulky adducts (e.g., PAH-DNA adducts). Polymorphic variants (Lys751Gln) may reduce repair efficiency, allowing tobacco-induced DNA lesions to persist and increasing mutation accumulation and cancer risk in smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Implicit gene × environment effect: reduced repair capacity magnifies the carcinogenic effect of tobacco exposure; meta-analyses generally underpowered to formally test interactions.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Variants impairing nucleotide excision repair (XPD Lys751Gln) are associated with increased lung cancer risk, supporting a mechanism where differential DNA repair capacity modulates smoker susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e72.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>XRCC1 Arg399Gln</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>XRCC1 Arg399Gln (base excision repair polymorphism)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A polymorphism in XRCC1, a base excision repair gene, associated with altered repair of single-strand breaks and base damage; some meta-analyses show increased lung cancer risk associated with the variant in certain ethnic groups.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (reviewed base-excision repair gene meta-analyses)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Lung-specific summary: XRCC1 Arg399Gln associated with lung cancer in Asians in pooled/meta-analyses; Table entry shows lung XRCC1 analysis based on 6 studies, N cases = 1,702 (OR ~1.34, CI reported in table).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>XRCC1 Arg399Gln (rs1799782/rs25487 region reported as Arg399Gln)</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>XRCC1 coordinates base excision repair of single-base damage and single-strand breaks; Arg399Gln variant may alter repair efficiency leading to persistence of tobacco-induced oxidative and alkylation damage.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>Lung (pooled results): OR ≈ 1.34 (95% CI 1.16–1.54) for certain comparisons in Table 2 (6 studies, N cases = 1,702); association strongest in Asians per discussion.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Tobacco exposure cited as source of oxidative/base damage; exposure measurement heterogeneous across studies and not standardized in the aggregated summaries.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td>Altered base excision repair capacity (reduced repair of oxidative and small-base lesions induced by tobacco smoke)</td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke (oxidative and alkylation damage substrates for BER pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>XRCC1 Arg399Gln variant may reduce efficiency of base excision repair, leading to accumulation of tobacco-induced oxidative DNA lesions and increased mutation risk; ethnic differences in allele frequency and effect noted, contributing to interindividual differences among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall; effect noted particularly in Asians)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Paper notes limited power to assess gene × smoking interactions but implies BER variants modulate response to tobacco-induced lesions.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Polymorphisms in base-excision repair genes (XRCC1 Arg399Gln) are associated with modestly increased lung cancer risk, suggesting reduced repair of tobacco-induced DNA damage contributes to differential susceptibility among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e72.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MDM2 SNP309</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MDM2 promoter polymorphism SNP309 (T>G, rs2279744)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A polymorphism in the MDM2 promoter that upregulates MDM2 expression and attenuates p53 tumor suppressor activity; associated with modestly increased lung cancer risk in pooled analyses and potentially different effects by smoking status.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (combined analyses of SNP309 and cancer risk reviewed)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Lung-specific meta-analysis summary: MDM2 SNP309 (GG vs TT) associated with lung cancer OR ≈ 1.27 (95% CI 1.12–1.44), p = 0.0002; 7 studies, N cases = 4,276 (Table 2).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>MDM2 SNP309 (promoter T>G polymorphism)</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>SNP309 increases MDM2 expression which binds and inhibits p53, reducing p53-mediated tumor suppression and DNA damage response.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>OR = 1.27 (95% CI 1.12–1.44), p = 0.0002 (lung cancer, 7 studies, N cases = 4,276) (Table 2)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Some follow-up studies examined cumulative cigarette smoking and stratified analyses by smoking (e.g., evidence stronger or differing when restricted to never smokers in a subsequent study), but primary meta-analysis reports genetic main effect.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td>Indirectly affects DNA damage response via p53 pathway inhibition</td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Smoking exposure considered in follow-up work as an effect modifier; tobacco carcinogens cause DNA damage that normally invokes p53 response suppressed by increased MDM2.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>MDM2 SNP309 elevates MDM2 levels, which bind and inhibit p53, impairing apoptosis and cell-cycle arrest in response to tobacco-induced DNA damage; this reduced tumor suppressor response can increase likelihood that DNA damage leads to malignant transformation in smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Review reports subsequent analyses showing effects may differ by smoking status (one follow-up study found support when restricted to never smokers and others examined cumulative smoking), indicating possible gene × smoking effect modification though evidence is mixed.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>A regulatory variant (MDM2 SNP309) that blunts p53-mediated responses is associated with increased lung cancer risk and provides a mechanism (attenuated damage response/apoptosis) explaining part of interindividual susceptibility among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e72.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MPO G463A</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Myeloperoxidase (MPO) G463A polymorphism</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A promoter polymorphism in MPO, an enzyme generating reactive oxidants; certain genotypes (AA) were associated with reduced lung cancer risk in pooled analyses, implying modulation of oxidative damage from tobacco smoke.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (HuGE pooled analyses reviewed)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Lung-specific pooled analysis summary: MPO G463A (AA vs GG) associated with OR = 0.71 (95% CI 0.57–0.88), p = 0.002; 19 studies, N cases = 5,608 (Table 2).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>MPO G463A promoter polymorphism</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>MPO produces reactive oxidants during inflammatory responses; promoter variants affect transcription and thus levels of oxidative species that can damage DNA generated in response to tobacco exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>OR = 0.71 (95% CI 0.57–0.88), p = 0.002 (lung cancer, 19 studies, N cases = 5,608) (Table 2)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Tobacco smoking referenced as a source of oxidative stress; studies included in pooled analysis varied in smoking measurement.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td>Modulation of oxidative metabolism (levels of reactive oxidants generated by MPO)</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td>Inflammation-mediated oxidative damage (MPO expressed in myeloid cells contributing to local oxidative stress)</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke enhances oxidative stress; MPO activity interacts with smoking-induced oxidative burden</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td>MPO G463A AA genotype (associated with lower MPO expression/activity)</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td>OR = 0.71 (95% CI 0.57–0.88), p = 0.002 (reduced lung cancer risk for AA vs GG in pooled analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>Lower MPO expression associated with G463A variant reduces generation of reactive oxidants during inflammation, decreasing oxidative DNA damage from tobacco exposure and thereby lowering lung cancer risk in carriers.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Implied interaction between MPO genotype and tobacco-induced oxidative stress; formal interaction testing limited in pooled analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Variants that reduce inflammation-driven oxidative damage (MPO G463A) are associated with lower lung cancer risk, supporting that interindividual differences in inflammatory/oxidative responses to smoking contribute to differential susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e72.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CYP2D6 poor metabolizer</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cytochrome P450 2D6 poor metabolizer phenotype</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>CYP2D6 polymorphisms giving rise to poor metabolizer status were associated with decreased lung cancer risk in pooled analyses, suggesting variation in activation/detoxification pathways alters risk from tobacco exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (reviewed pooled analyses targeting metabolic enzymes and lung cancer)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Pooled/meta-analyses summarized in this review; for lung CYP2D6 poor vs extensive metabolizer comparison: 17 studies, N cases = 7,504 (Table 2).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>CYP2D6 poor metabolizer genotype (loss-of-function alleles aggregated as 'poor vs extensive')</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>CYP2D6 participates in metabolism of some carcinogens and xenobiotics; poor metabolizer genotype reduces certain bioactivation pathways, potentially lowering formation of reactive carcinogens from tobacco components.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>OR = 0.69 (95% CI 0.52–0.90), p = 0.0080 (lung cancer; 17 studies, N cases = 7,504) (Table 2)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Tobacco exposure as primary environmental substrate; heterogeneously measured across constituent studies.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td>Phase I metabolism (reduced bioactivation of certain tobacco procarcinogens due to poor CYP2D6 activity)</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke (source of procarcinogens metabolized by CYP2D6)</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td>CYP2D6 poor metabolizer phenotype</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td>OR = 0.69 (95% CI 0.52–0.90), p = 0.008 (reduced lung cancer risk compared with extensive metabolizers)</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>Poor CYP2D6 metabolic activity reduces bioactivation of specific tobacco procarcinogens, leading to lower levels of DNA-reactive metabolites and a reduced risk of smoking-related lung cancer in carriers.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Suggestive gene × environment effect: metabolic genotype modifies the carcinogenic impact of tobacco exposure; formal interaction tests limited.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Variation in phase I metabolic capacity (CYP2D6 poor metabolizer) can be protective against lung cancer, demonstrating that differences in metabolic activation of tobacco carcinogens partly explain why only some smokers develop lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e72.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e72.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain why some smokers develop lung cancer while others do not, including genetic factors, exposure characteristics, environmental co-factors, protective factors, and mechanistic explanations for differential susceptibility.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>XPA G23A</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>XPA G23A (nucleotide excision repair polymorphism)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A polymorphism in XPA, a core nucleotide excision repair gene, associated with reduced lung cancer risk in pooled analyses, implying variation in repair-related susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genetic Susceptibility to Cancer: the Role of Polymorphisms in Candidate Genes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis / pooled analyses (DNA repair gene meta-analyses reviewed)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Pooled analyses summarized for lung cancer: XPA G23A (GA vs AA) OR = 0.73 (95% CI 0.61–0.89), p = 0.0011; 7 studies, N cases = 1,913 (Table 2).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor</strong></td>
                            <td>XPA G23A</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factor_description</strong></td>
                            <td>XPA participates in damage recognition/verification in nucleotide excision repair; promoter/UTR variants may alter expression or function affecting repair of bulky adducts from tobacco smoke.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_risk_estimate</strong></td>
                            <td>OR = 0.73 (95% CI 0.61–0.89), p = 0.0011 (lung cancer; 7 studies, N cases = 1,913) (Table 2)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_measure</strong></td>
                            <td>Tobacco smoke as source of bulky adducts; exposure measurement varied across component studies.</td>
                        </tr>
                        <tr>
                            <td><strong>dose_response_relationship</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>percentage_smokers_develop_cancer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>metabolic_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_factor</strong></td>
                            <td>Altered nucleotide excision repair (XPA variant associated with reduced risk in pooled analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>immune_inflammatory_factor</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_cofactor</strong></td>
                            <td>Tobacco smoke (source of bulky DNA adducts repaired by NER pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor</strong></td>
                            <td>XPA G23A GA genotype</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factor_effect</strong></td>
                            <td>OR = 0.73 (95% CI 0.61–0.89), p = 0.0011 (reduced lung cancer risk)</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_explanation</strong></td>
                            <td>Variant XPA alleles may alter NER activity or regulation and thus change the balance between effective repair of tobacco-induced bulky DNA adducts and persistence of mutations; some alleles are associated with lower risk, indicating complex functional effects.</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_subtype</strong></td>
                            <td>Not specified (lung cancer overall)</td>
                        </tr>
                        <tr>
                            <td><strong>interaction_effects</strong></td>
                            <td>Implied modification of tobacco carcinogen effects via repair capacity; interaction testing limited in pooled analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Polymorphisms in NER pathway genes (XPA) can be associated with lower lung cancer risk, indicating that variability in DNA repair responses contributes to differential susceptibility among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>MDM2 SNP309 and cancer risk: a combined analysis <em>(Rating: 2)</em></li>
                <li>Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis <em>(Rating: 2)</em></li>
                <li>Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis <em>(Rating: 2)</em></li>
                <li>Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review <em>(Rating: 2)</em></li>
                <li>CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: A meta-analysis <em>(Rating: 2)</em></li>
                <li>Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>